Skip to main content
TipRanks
Go Ultimate75% OFF

Ran Frenkel Insider Profile

4 Followers

Ran Frenkel, EVP, Chief Dev. Officer at Karyopharm Therapeutics, holds 168.29K shares in Karyopharm Therapeutics (Ticker: KPTIQ).

Ran Frenkel's Trading History

KPTIQ
Karyopharm Therapeutics
Mar 02, 2022EVP, Chief Dev. OfficerUninformative Buy―$4.21K
KPTIQ
Insider Shares: 168.29K (0.00%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Mar 02, 2022Informative Sell$17.01K1,663$10.23+50.70%
Mar 02, 2022Uninformative Buy$0.0068,250$0.00―
Feb 22, 2022Informative Sell$35.50K2,929$12.12+69.00%
Feb 09, 2022Uninformative Sell$19.63K1,991$9.86―
Mar 01, 2021Uninformative Buy$0.0022,013$0.00―

You May Also Like

Ran Frenkel insider profile FAQ

What is the percentage of profitable transactions made by Ran Frenkel?
The percentage of profitable transactions made by Ran Frenkel is 57%.
What is the average return per transaction made by Ran Frenkel?
The average return per transaction made by Ran Frenkel is 8.90%.
What stocks does Ran Frenkel hold?
Ran Frenkel holds: KPTIQ stocks.
What was Ran Frenkel's most profitable transaction?
Ran Frenkel’s most profitable transaction was an Informative Sell of KPTIQ stock on February 22, 2022. The return on the trade was 69.00%.
What is Ran Frenkel's role in Karyopharm Therapeutics?
Ran Frenkel's role in Karyopharm Therapeutics is EVP, Chief Dev. Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.